Elevated levels of free tissue factor pathway inhibitor antigen in cases of disseminated intravascular coagulation caused by various underlying diseases

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 1, 2001, Pages 1-8

  Asakura, H ^a   Ontachi, Y ^a   Mizutani, T ^a   Kato, M ^a   Saito, M ^a   Morishita, E ^a   Yamazaki, M ^a   Suga, Y ^a   Takami, A ^a   Miyamoto, K ^a   Nakao, S ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Disseminated intravascular coagulation; Tissue factor pathway inhibitor

Indexed keywords

ANTIGEN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN DEGRADATION PRODUCT; HEPARIN; LIPOPROTEIN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

CASE-CONTROL STUDIES; DISSEMINATED INTRAVASCULAR COAGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS; MULTIPLE ORGAN FAILURE; NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 17744389784     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200101000-00001     Document Type: Article

References (37)

1. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
2. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandems Kunitz-type inhibitory domains
3. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor
4. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis
5. Purification and properties of heparin releasable lipoprotein associated inhibitor
6. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma
7. Tissue factor pathway inhibitor activity in human plasma: Measurement of lipoprotein-associeasurement of lipoprotein-associated and free form in hyperlipidemia
8. Extrinsic pathway inhibitor after heparin injection: Increased response in cancer patients
9. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients
10. Disseminated intravascular coagulation; findings in 346 patients
11. Immunologic measurement of antithrombin III-heparin cofactor and α2 microglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy
12. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant
13. Human plasma extrinsic pathway inhibitor activity: II Plasma levels in disseminated intravascular coagulation and hepatocellular disease
14. Plasma antigen levels of the lipoprotein associated coagulation inhibitor in patient samples
15. An antitissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free form TFPI but not lipoprotein-associated forms in plasma
16. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan
17. On the revised form of the confirmatory tests in diagnosis criteria for DIC
18. Plasma levels of soluble thrombomodulin increase in cases of disseminated intravascular coagulation with organ failure
19. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation
20. Gerinnungsphysiologische schnell methode zur bestimmung des fibrinogens
21. Determination of human thrombin-antithrombin III complex in plasma with an enzyme linked immunosorbent assay
22. Monoclonal antibodies to discrete regions in α2-plasmin inhibitor
23. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia
24. Thrombomodulin is present in human plasma and urine
25. Plasma thrombomodulin in health and diseases
26. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: Comparison of its behavior with tissue plasma factor
27. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
28. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation
29. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor
30. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: Effect on TFPI activity
31. Increased truncate form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
32. Localization of topically applied TFPI binding sites in an intimectomized microvessel
33. A novel degradation pathway of tissue factor pathway inhibitor: Incorporation into fibrin clot and degradation by thrombin
34. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: Effect of the tissue factor pathway inhibitor
35. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
36. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons
37. Elevated levels of tissue factor pathway inhibitor in acute non-lymphoblastic leukemia patients with disseminated intravascular coagulation